Featured publication

Tracking the developments in the fields of law and economics, public policy, and business strategy.

FALL 2025

View Issue

Search Insights

Latest Insights

Article  |  March 9, 2026

Political, Economic, and Financial Crime Risk Trends in Latin America

Enforcement and regulatory conditions observed during 2025 continue to influence cross border risk exposure across Latin America in 2026. These conditions are particularly relevant for financial institutions, illicit supply chains, and organized criminal activity, and continue to shape how corporate governance, regulatory exposure, and private sector risk are evaluated.

Read More
Article  |  March 6, 2026

The Economics of Remedies to Restore Competition in Epic v. Google

Epic Games’ (“Epic”) suit against Google over the Google Play Store (GPS) and its payment system, Google Play Billing (GPB), continues to capture attention as one of the most closely watched recent U.S. antitrust battles. Now, however, the focus of the case has shifted from Epic’s jury win and Judge Donato’s injunction remedies to the parties’ settlement and proposed remedy changes. The parties’ proposal has engendered judicial skepticism, amici involvement, opinions from Court-appointed experts, and economic scrutiny that may derail the parties’ proposed deal.

Read More

See All Insights

Events

See All Events
featured Engagements

Eric Poer Reflects on a Historic Forensic Investigation That Drove Sweeping Reforms at Wells Fargo in the Wake of Historic Fraud Scandal 

Eric Poer, an internationally-recognized forensic accounting, investigations, and disputes expert, led the forensic accounting and data analytics team retained to support A&O Shearman in conducting an independent investigation into Wells Fargo’s sales practices—an inquiry launched in response to one of the most significant financial consumer fraud scandals in U.S. history.

Read More
View All Engagements
featured Engagements

Biopharmaceutical Reasonable Royalties on Trial

When our client, a biopharmaceutical company, had exclusively licensed a patent for a novel type of cancer immunotherapy, a competitor undertook substantial efforts to be first to market for its lead indication despite being aware of potential infringement claims against its therapy. Upon the competitor achieving FDA approval, our client filed patent infringement claims. After an eight-day trial, the jury returned a verdict in favor of our client with a damages award that precisely matched the trial testimony.

Read More
View All Engagements

Media Contact

If you would like to schedule an interview or would like more information about our firm and individual experts, please contact:

Nathan Jenks
Director of Marketing & Communications
Email: njenks@secretariat-intl.com